NCT03128593View on ClinicalTrials.gov

A Study of JR-141 in Patients With Mucopolysaccharidosis Type II

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

October 4, 2017

Study Completion Date

October 4, 2017

Conditions
Mucopolysaccharidosis II
Interventions
DRUG

JR-141

IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week

Trial Locations (8)

501-1194

Gifu Clinical site, Gifu

830-0011

Fukuoka Clinical site, Kurume

105-8471

Tokyo clinical site1, Minato

545-8586

Osaka Clinical site1, Osaka

330-8777

Saitama Clinical site, Saitama

157-8535

Tokyo clinical site2, Setagaya City

Osaka Clinical site2, Suita

683-8504

Tottori Clinical site, Yonago

Sponsors
All Listed Sponsors
lead

JCR Pharmaceuticals Co., Ltd.

INDUSTRY

NCT03128593 - A Study of JR-141 in Patients With Mucopolysaccharidosis Type II | Biotech Hunter | Biotech Hunter